Scott Tykodi, MD, PhD
, physician at Seattle Cancer Care Alliance, associate professor in the Division of Medical Oncology at University of Washington Medicine, and associate professor in the Clinical Research Division at the Fred Hutchinson Cancer Research Center
, discusses biomarker signatures associated with response rate in the KEYNOTE-427 clinical trial using pembrolizumab for renal cell carcinoma (RCC). Dr. Tykodi explains an RNAseq dataset for the trial cohort defined 11 discrete pathways. One of these pathways, a T-cell inflamed gene panel, showed a higher incidence response rate but did not show a statistically significant increase in progression-free survival.
Learn more by clicking here